Clinical strategy in humans and animals for an oncology start-up company

Situation

• Biotech developing cutting-edge technologies and novel medicines in cancer by interfering with DNA damage sensing, signaling and repair processes.
• Already promising preclinical proof-of-concept but there was a need to identify the most attractive therapeutic segments before drafting a comprehensive pre-clinical and clinical development plan

Bionest Contribution

• Provided a clear understanding of current and future therapeutic strategies for the targeted indications: analysis of epidemiology data, international guidelines and interviews with prescribing oncologists
• Positioned company’s products by scoping their market potential and assessing their competitive profile

Key Results

• Bionest conclusions were negative for the initially targeted therapeutic indications
• Reorientation of resources to most promising type of cancers where company’s technology has a clear competitive advantage